Douglas A. Dachille, Director at BridgeBio Pharma, Inc. (BBIO), bought 10,000 shares at $8.19 ($82K) on 2022-03-14, disclosed to the SEC on 2022-03-16.
Open-market purchase of $82k BBIO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| AIG | SELL | 2021-06-04 | $2.1M | — | Filing → |